Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Shares of Medtronic Inc. (MDT - Analyst Report) rose 0.5% following the U.S. Food and Drug Administration (FDA) approval of its MiniMed 530G, better known as the “artificial pancreas”. The device is designed to suspend insulin delivery in diabetes patients when blood-sugar levels are very low.

This is good news for diabetic patients over 16 years of age because lower than normal blood sugar level or hypoglycemia could be fatal for them. They should now be grateful to Medtronic and its MiniMed 530G, which combines an insulin pump with a sensor that sends a signal when sugar levels are below normal and even stops insulin delivery for two hours, particularly at night when they are asleep or unable to respond. Post FDA approval, the device will be developed for children aged 2 years and older.

The device has been launched for the first time in the U.S. However, it has been sold outside the U.S. as the MiniMed Veo System since 2009.

In the human body, insulin hormone is produced by pancreas, which converts blood sugar to energy. Due to diabetes, insulin-producing cells in the pancreas are destroyed causing patients to maintain proper blood sugar by injecting insulin. As a result, scientists have been struggling for years to develop technologies for automating insulin delivery.

Medtronic received the FDA approval for the device a week after getting a warning letter from the authority regarding issues related to manufacturing processes following an inspection of the company’s diabetes facility in Northridge, Calif. However, MDT has promised to address these issues as soon as possible.

Currently, MDT retains a Zacks Rank #3 (Hold). While we remain on the sidelines about the company, other medical product stocks that worth a look include Trinity Biotech plc (TRIB - Snapshot Report) with a Zacks Rank #1 (Strong Buy), and Boston Scientific Corporation (BSX - Analyst Report) and Cytosorbents Corporation (CTSO), both with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%